Clinical trials: Pandemic Influenza, active
Influenza A
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).
- Trial name
- PANDA (NCT07128615)
- Testing
- AZD4117, AZD5315
- Where
- 14 sites in United States
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Influenza
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
- Trial name
- NCT07496450
- Testing
- mRNA-1018-H5
- Where
- 35 sites in United States, United Kingdom
- Volunteers
- 4,050 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza (Healthy Volunteers)
Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness
The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza…
- Trial name
- NCT07305207
- Testing
- Intranasal inoculation of RG-A/Texas/71/2017 (H3N2) influenza in each naris on Day 1 of the study.
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza (Pandemic), Avian Influenza
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the…
- Conditions
- Influenza (Pandemic), Avian Influenza, Vaccination
- Trial name
- PIVOT (NCT07240558)
- Testing
- H5N1 vaccine (Arepanrix, GSK)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Influenza Prevention, Pandemic Influenza Prevention
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu.
- Trial name
- NCT07111078
- Testing
- VRC-FLUMOS0122-00-VP, ALFQ
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID 19, Respiratory Synctial Virus
COMMUNITY - the COVID-19 Immunity Study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients.
- Conditions
- COVID 19, Respiratory Synctial Virus, Influenza Virus, SARS-CoV-2 Virus
- Trial name
- COMMUNITY (NCT06784739)
- Testing
- Blood sampling, Mucosal sampling, PCR-test
- Where
- 2 sites in Sweden
- Volunteers
- 2,420 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Respiratory Infections, COVID-19
Volatile Organic Compounds Analysis by GC-MS for Diagnostic of Hospitalised Patients With Respiratory Infections Using Exhaled Breath
Emerging respiratory diseases represent a global threat. Viruses such as influenza and coronaviruses have been the main drivers of pandemics over the past century.
- Conditions
- Respiratory Infections, COVID-19, Influenza Virus Infection, Legionella Pneumophila Infections
- Trial name
- VORTEX-2 (NCT07352462)
- Testing
- Volatile Organic compounds (VOC) analysis in Exhaled breath using GC-MS
- Where
- 7 sites in France
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
covid19 Infection, Influenza, Human
Covid-19 and Influenza Oral Vaccine Study
The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery.
- Trial name
- NCT06355232
- Testing
- Covid-19 vaccine, Influenza vaccine
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Pandemic Influenza Immunization, Healthy Volunteers
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against…
- Trial name
- NCT06907511
- Testing
- Pandemic flu H5 HA mRNA SD2 vaccine
- Where
- 13 sites in United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Human
Vaccine Pandemic Preparedness Through Airway Immunology Characterization
The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49.
- Trial name
- VAXXAIR (NCT05921448)
- Testing
- Vaxigripetra, Flumist
- Where
- 7 sites in Denmark, United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Copenhagen Respiratory Research